Asthma Management across the Adult Lifespan (GINA Guidelines)

Asthma Management across the Adult Lifespan (GINA Guidelines)

Pathophysiology and Clinical Phenotypes

Asthma is a heterogeneous chronic inflammatory disorder of the airways characterized by variable expiratory airflow limitation and bronchial hyperresponsiveness. Pathophysiologically, complex interactions between eosinophils, T-helper 2 lymphocytes, mast cells, and neutrophils trigger mucosal edema, bronchospasm, hypersecretion of viscous mucus, and subepithelial fibrosis leading to progressive airway remodeling.

Asthma presents across several distinct clinical phenotypes:

• Allergic (T2-High) Asthma: Most common phenotype, featuring early onset, elevated serum IgE, positive allergy skin testing, and eosinophilic airway inflammation. It responds exceptionally well to inhaled corticosteroids (ICS).
• Non-Allergic (T2-Low) Asthma: Often seen in adults with neutrophilic or paucigranulocytic sputum profiles. Demonstrates reduced short-term responsiveness to standard ICS.
• Adult-Onset (Late-Onset) Asthma: Frequently presents in adult females without atopic histories, often requiring higher ICS doses or secondary add-on agents. Occupational exposures must be thoroughly investigated.
• Asthma with Fixed Airflow Limitation: Results from chronic unmanaged inflammation causing permanent structural airway remodeling.
• Obesity-Associated Asthma: Marked respiratory symptoms with prominent exertional dyspnea and minimal baseline eosinophilic inflammation.

Diagnostic Evaluation & Spirometric Criteria

Diagnostic confirmation requires characteristic respiratory symptoms (wheezing, dyspnea, chest tightness, cough) paired with objective evidence of variable expiratory airflow limitation.

Spirometry is the diagnostic gold standard. Baseline obstruction is defined by a reduced forced expiratory volume in 1 second to forced vital capacity (FEV1/FVC) ratio (< 0.70–0.75 in adults).

Bronchodilator Reversibility Testing

Reversibility is evaluated by performing baseline spirometry, administering 4 puffs (400 mcg) of albuterol via MDI with spacer, and repeating spirometry 10–15 minutes later. A positive bronchodilator reversibility test in adults requires:

• An increase in FEV1 of >= 12% AND >= 200 mL relative to baseline.

Alternatively, diurnal peak expiratory flow (PEF) variability > 10% supports diagnosis. Differential diagnoses in adults include vocal cord dysfunction, GERD, post-nasal drip, heart failure, and pulmonary embolism.

GINA Guideline Treatment Tracks: Track 1 vs. Track 2

The Global Initiative for Asthma (GINA) guidelines strictly advise against SABA-only monotherapy due to increased risks of severe exacerbations and asthma-related mortality. GINA outlines two management pathways based on reliever selection:

Track 1: Preferred Strategy (ICS-Formoterol Reliever)

Track 1 is preferred across all treatment steps. Patients use low-dose ICS-formoterol as their as-needed reliever. Formoterol is a long-acting beta2-agonist (LABA) with rapid onset (1–3 minutes). Combining formoterol with an ICS ensures patients receive anti-inflammatory medication with every reliever dose, suppressing airway inflammation and lowering exacerbation risk.

Track 2: Alternative Strategy (SABA Reliever)

Track 2 is an alternative when Track 1 is unavailable or unsuited. Patients use a SABA (albuterol) as needed for relief but MUST take a regular daily ICS controller. Strict adherence must be verified before prescribing Track 2.

Stepwise Management Escalation

Maintenance and Reliever Therapy (MART): In Steps 3–4 of Track 1, patients use the same ICS-formoterol inhaler for daily maintenance and as-needed relief.

Step 5 Biologic Therapies

For severe uncontrolled asthma, targeted biologics are selected by phenotype: anti-IgE (omalizumab), anti-IL5/IL5R (mepolizumab, benralizumab), anti-IL4R (dupilumab), or anti-TSLP (tezepelumab).

Assessment of Asthma Control and Risk

Evaluate symptom control over the past 4 weeks across four domains:

1. Daytime symptoms > 2x/week?
2. Night waking due to asthma?
3. Reliever needed > 2x/week?
4. Any activity limitation?

• Well Controlled: 0 items.
• Partly Controlled: 1–2 items.
• Uncontrolled: 3–4 items.

Acute Exacerbation Management

Acute exacerbations feature progressive dyspnea, wheezing, cough, and decreased FEV1/PEF. Outpatient management includes:

• Short-Acting Bronchodilators: Albuterol 4–10 puffs via MDI with valved holding chamber every 20 minutes for 1 hour.
• Systemic Corticosteroids: Early oral steroids speed resolution. Regimen: prednisone 40–50 mg orally daily for 5–7 days. Tapering is unnecessary for courses under 14 days.
• Oxygen: Titrate to maintain SpO2 93–95%.

Self-Management Education and Action Plans

Patient self-management education empowers adults to monitor control and respond early to exacerbations:

• Written Asthma Action Plan: Formulate a individualized plan based on symptom triggers and peak expiratory flow (PEF) monitoring.
• PEF Zones: Green Zone (80–100% of personal best; continue baseline controller), Yellow Zone (50–79% of personal best; caution, step up reliever and consider starting oral prednisone burst), Red Zone (< 50% of personal best; medical alert, initiate emergency reliever doses and seek urgent care).

Geriatric Nuances and Special Considerations

• Diagnostic Pitfalls: Asthma is frequently underdiagnosed in older adults, misattributed to heart failure ("cardiac asthma") or COPD. Asthma-COPD Overlap (ACO) occurs in patients with atopy and smoking history.
• Inhaler Device Selection: Grip strength, arthritis, and peak inspiratory flow rate (PIFR) dictate device choice. Dry powder inhalers (DPIs) require rapid inhalation (PIFR > 60 L/min). Metered-dose inhalers (MDIs) require hand-breath coordination; prescribe a valved holding chamber (spacer) with MDIs for older adults.
• Pharmacological Risks: Monitor for high-dose ICS side effects (osteoporosis, cataracts, skin bruising) and drug interactions (non-selective beta-blockers triggering bronchospasm, NSAIDs triggering aspirin-exacerbated respiratory disease).